Technavio has been monitoring the global type 1 diabetes drugs market since 2016 and the market is poised to grow by USD 12 billion during 2019-2023, progressing at a CAGR of over 7% during the forecast period. Read the 127-page research report with TOC on "Type 1 Diabetes Drugs Market Analysis Report by Product (Long-acting insulins, Rapid-acting insulins, Pre-mixed insulins, and Non-insulin drugs), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019 - 2023." People who experience mutations in the genes encoding the human leukocyte antigen (HLA) such as the HLA-DQA1, HLA-DQB1, and HLA-DRB1 genes are also susceptible to type 1 diabetes. Major Five Type 1 Diabetes Drugs Market Companies:. Astellas Pharma. Astellas Pharma is headquartered in Japan and operates the business under the Pharmaceuticals segment.
2 other references
Latest Stories From Referenced Companies
Dicerna™ Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
Feb 27, 2020